Current Oncology Reports

, Volume 4, Issue 5, pp 415-423

First online:

Changing role and decreasing size: Current trends in radiotherapy for hodgkin’s disease

  • Joachim YahalomAffiliated withDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Radiotherapy, the first cancer treatment modality that offered cure, is still considered to be the most effective “single agent” in treating Hodgkin’s disease (HD). Yet, the role of radiotherapy in HD has changed dramatically with the advent of effective combination chemotherapy and the rising concern of long-term complications associated with successful treatment of HD. The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design.